In the ASSAIL-MI (ASSessing the effect of Anti-IL-6 treatment in Myocardial Infarction) trial we showed that mitigation of inflammation by blocking the interleukin-6 (IL-6) receptor with the monoclonal antibody tocilizumab leads to improved outcomes in patients with MI (5). The gene discussed is IL6; the disease is myocardial infarction.